clinical trial · NCT05327114
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Janssen Research & Development, LLC·phase3·recruiting·n = 201
Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNipocalimabPlacebo
brief summary
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
started
Sep 23, 2022
primary completion
May 14, 2027
completion
Nov 27, 2028
last updated
Sep 25, 2026
official title
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol